atezolizumab + cobimetinib + vemurafenib

Atezolizumab + cobimetinib + vemurafenib is an FDA-approved triple combination regimen for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. - **Atezolizumab** is a monoclonal antibody immune checkpoint inhibitor targeting PD-L1, thereby enhancing T cell-mediated anti-tumor immune responses. - **Cobimetinib** is a small molecule, reversible inhibitor of MEK1 and MEK2 kinases, which are part of the MAPK (RAS/RAF/MEK/ERK) cascade, primarily used to suppress downstream signaling from mutated BRAF. - **Vemurafenib** is a small molecule kinase inhibitor selective for BRAF V600-mutant kinase, blocking abnormal cell proliferation in BRAF-mutant melanoma. The combination aims to maximize anti-tumor activity: cobimetinib and vemurafenib together block the MAPK pathway to inhibit tumor cell proliferation and induce apoptosis; atezolizumab counteracts adaptive immune resistance induced by MAPK pathway inhibition, improving progression-free survival and duration of response versus targeted therapy alone[1][3][4][5][7].

Brand names

TecentriqZelborafCotellic

Other names

cobimetinib + atezolizumab + vemurafenib